HistoSonics’ phased commercial rollout of the Edison system will initially target centers specializing in liver tumor treatment.
HistoSonics wins Europe’s CE mark for histotripsy system Read More »
Payer mix changes, mostly from people dropping out of Affordable Care Act plans, caused HCA to lose $400 million in the second quarter — much more than the company (or its investors) had expected.
HCA cuts 2026 earnings forecast on insurance coverage losses Read More »
The agency’s finalized recommendations for clinical testing of psychedelic compounds for mental health could pave the way for companies like Compass Pathways, whose psilocybin-based therapy for treatment-resistant depression could win approval as early as this year.
Final psychedelics guidance suggests FDA is ‘receptive’ to helping companies succeed Read More »
Biogen touted an “unprecedented” drop in tau in a Phase 2 trial, backing the company’s decision to take diranersen to Phase 3 despite a missed primary endpoint and seemingly supporting the anti-tau approach.
AAIC 2026: Biogen delivers hope, validation with anti-tau Alzheimer’s win Read More »
Leqembi Iqlik can now be given at home throughout the entire course of treatment, setting it apart from Eli Lilly’s Kisunla, the only other anti-amyloid Alzheimer’s disease therapy on the market.
Biogen, Eisai win FDA nod for starter dose of subcutaneous Leqembi Read More »
Through the proposal, the FDA could clear barriers to distributed manufacturing approaches intended to enhance emergency preparedness and supply chain resilience.
FDA proposes streamlined requirements for ‘hub-and-spoke’ manufacturing models Read More »
Dizal Pharmaceutical’s Zegfrovy is approved in the U.S. for locally advanced or metastatic non-small cell lung cancer. For $600 million upfront, AstraZeneca will gain global rights to advance and commercialize the asset.
AstraZeneca takes another China trip, picking Dizal’s lung cancer drug for up to $1.5B Read More »
Spero Therapeutics is putting over $1 billion on the line in exchange for rights to develop SP001, an anti-CD40L antibody, for IgG4-related disease. A Phase 2 study is planned for the second quarter of 2027.
Spero bets up to $1.1B for Innovent’s autoimmune antibody Read More »
In this bonus episode, BioSpace Managing Editor Jef Akst and Angela Gabriel, content manager, life sciences careers, look at the Q2 job market and discuss encouraging signs for job seekers.
La impresión textil parece un proceso directo: se sube un archivo, se elige una prenda y se recibe el producto. En realidad, el resultado depende de varias decisiones técnicas tomadas antes de producir. La pregunta clave es sencilla: ¿el archivo sirve para el …
Del archivo digital al tejido: decisiones técnicas que cambian el resultado Read More »
